Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP1CA | P62136 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MARS1 | P56192 | 4/20 | 0.54 |
| ▸ | RPA1 | P27694 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765058 | 0.87 | PPP1CA (0.77) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL1764957 | 0.86 | PPP1CA (0.75) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL27958107 | 0.85 | PPP1CA (0.77) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL1764946 | 0.85 | CHRNA7 (0.52) | PPP1CA | |
| SCHEMBL1110792 | 0.84 | PPP1CA (0.68) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL1765444 | 0.84 | PPP1CA (0.72) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL16921449 | 0.84 | PPP1CA (0.65) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL1765063 | 0.83 | PPP1CA (0.82) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL1764885 | 0.83 | PPP1CA (0.67) | PPP1CAL3MBTL1MEN1KMT2AATM | |
| SCHEMBL1764976 | 0.83 | PPP1CA (0.70) | PPP1CAL3MBTL1MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| CN-101977908-A | (pyrazolyl carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases | AICURIS GMBH & CO KG | 2011-02-16 | — | — | CN | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | PPP1CA 1664/4885L3MBTL1 1446/4885MEN1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.